Immusoft

Cell engineering
#Cell therapy #Engineered cells #Immusoft #Phase I trial #Rare disease

World’s first engineered B cell therapy enters human trials

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Developer Immusoft has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the therapy, designated ISP-001, in this indication. Read More

#Editor's Choice #News